CoChat

Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

There is a close relationship between the gut microbiota and metabolic disorders. In this study, acute administration of the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide to mice increased the cecal levels of caseinolytic protease B, a component of Escherichia coli , and of norepinephrine. Chemical sympathectomy blocked these events. Norepinephrine was found to pass into the intestinal lumen in vitro. c-Fos staining of the intermediolateral nucleus was identified as indirect evidence of sympathetic nervous system activation of the intestinal tract by GLP-1RA. Under normal conditions, the increase in E. coli did not affect the host. However, in mice with colitis, bacterial translocation was observed with attenuation of tight junction gene expression. This is the first study to investigate the unique underlying mechanisms related the effects of GLP-1RA on changes in the gut bacterium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-021-88612-x

Cites

Statistics

Figures

Figure 1 Acute administration of liraglutide increases E. coli levels in mice. Relative expression of (A) major gut microbiota (phylum level) and (B) ClpB and E. coli (16S rRNA) in cecal contents with or without acute liraglutide administration (control, n = 7; liraglutide, n = 7). (C) Correlation between the relative expression of ClpB and E. coli (16S rRNA) in cecal contents (n = 14). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by non-paired t-test (A and B) or linear regression analysis (C). The coefficient of determination is denoted as R2. All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).
Figure 1 Acute administration of liraglutide increases E. coli levels in mice. Relative expression of (A) major gut microbiota (phylum level) and (B) ClpB and E. coli (16S rRNA) in cecal contents with or without acute liraglutide administration (control, n = 7; liraglutide, n = 7). (C) Correlation between the relative expression of ClpB and E. coli (16S rRNA) in cecal contents (n = 14). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by non-paired t-test (A and B) or linear regression analysis (C). The coefficient of determination is denoted as R2. All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).CC BY · PubMed Central
Figure 2 Liraglutide increases NE levels in cecal contents via activation of sympathetic nerves. (A) Relative expression of ClpB in cecal contents in saline and medetomidine (α2 receptor agonist [α2RA]) groups with or without acute liraglutide administration (saline control, n = 7; saline liraglutide, n = 6; α2RA control, n = 5; α2RA liraglutide, n = 5). (B) Measurement of norepinephrine concentrations in cecal contents and plasma in saline and medetomidine groups with or without acute liraglutide administration (saline control, n = 4; saline liraglutide, n = 5; α2RA control, n = 5; α2RA liraglutide, n = 8). (C) Relative expression of ClpB in cecal contents with or without acute liraglutide administration under bilateral adrenalectomy (ADX) (control-ADX, n = 8; liraglutide-ADX, n = 8). (D) Measurement of norepinephrine concentrations in cecal contents and plasma with or without acute liraglutide administration under ADX (control-ADX, n = 4; liraglutide-ADX, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by two-way ANOVA with multiple comparison test (A and B) or non-paired t-test (C and D). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).
Figure 2 Liraglutide increases NE levels in cecal contents via activation of sympathetic nerves. (A) Relative expression of ClpB in cecal contents in saline and medetomidine (α2 receptor agonist [α2RA]) groups with or without acute liraglutide administration (saline control, n = 7; saline liraglutide, n = 6; α2RA control, n = 5; α2RA liraglutide, n = 5). (B) Measurement of norepinephrine concentrations in cecal contents and plasma in saline and medetomidine groups with or without acute liraglutide administration (saline control, n = 4; saline liraglutide, n = 5; α2RA control, n = 5; α2RA liraglutide, n = 8). (C) Relative expression of ClpB in cecal contents with or without acute liraglutide administration under bilateral adrenalectomy (ADX) (control-ADX, n = 8; liraglutide-ADX, n = 8). (D) Measurement of norepinephrine concentrations in cecal contents and plasma with or without acute liraglutide administration under ADX (control-ADX, n = 4; liraglutide-ADX, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by two-way ANOVA with multiple comparison test (A and B) or non-paired t-test (C and D). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).CC BY · PubMed Central
Figure 3 NE from sympathetic nerves passes into the intestinal lumen. (A) Measurement of norepinephrine concentration on the mucosal side before and after KCl administration to the serosal side of the cecum (control, n = 6; KCl, n = 5). (B) Change in norepinephrine concentration on the mucosal side after the administration of various drugs to the serosal side of the cecum (control, n = 6; KCl, n = 5; exendin-4, n = 4; carbachol, n = 4; capsaicin, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by two-way ANOVA with multiple comparison (A) or one-way ANOVA with multiple comparison (B). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).
Figure 3 NE from sympathetic nerves passes into the intestinal lumen. (A) Measurement of norepinephrine concentration on the mucosal side before and after KCl administration to the serosal side of the cecum (control, n = 6; KCl, n = 5). (B) Change in norepinephrine concentration on the mucosal side after the administration of various drugs to the serosal side of the cecum (control, n = 6; KCl, n = 5; exendin-4, n = 4; carbachol, n = 4; capsaicin, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by two-way ANOVA with multiple comparison (A) or one-way ANOVA with multiple comparison (B). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).CC BY · PubMed Central
Figure 4 Liraglutide enhances c-Fos staining, not only in the AP/NTS, but also in the IML. Representative image of immunohistochemistry for c-Fos in (A) the AP and NTS and (B) the IML with or without acute liraglutide administration. In (A), the top and middle left images are the original magnification, whereas the middle right and lower images are the original magnification × 40. Scale bars: 500 µm in the top image, 100 µm in the middle left image, and 50 µm in the middle right and lower images in (A). All images are the original magnification in (B). Scale bars: 200 µm in the top image, 20 µm in the lower image in (B). Arrows indicate c-Fos staining in (B).
Figure 4 Liraglutide enhances c-Fos staining, not only in the AP/NTS, but also in the IML. Representative image of immunohistochemistry for c-Fos in (A) the AP and NTS and (B) the IML with or without acute liraglutide administration. In (A), the top and middle left images are the original magnification, whereas the middle right and lower images are the original magnification × 40. Scale bars: 500 µm in the top image, 100 µm in the middle left image, and 50 µm in the middle right and lower images in (A). All images are the original magnification in (B). Scale bars: 200 µm in the top image, 20 µm in the lower image in (B). Arrows indicate c-Fos staining in (B).CC BY · PubMed Central
Figure 5 In DSS colitis, liraglutide attenuates tight junction gene expression in the cecum. Relative expression of cecal genes with or without acute liraglutide administration (A) in wild-type mice (control, n = 6–8; liraglutide, n = 5–8), (B) in wild-type mice (control, n = 7; liraglutide, n = 9), and (C) in TLR4KO mice with DSS colitis (control, n = 5; liraglutide, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by non-paired t-test (A–C). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).
Figure 5 In DSS colitis, liraglutide attenuates tight junction gene expression in the cecum. Relative expression of cecal genes with or without acute liraglutide administration (A) in wild-type mice (control, n = 6–8; liraglutide, n = 5–8), (B) in wild-type mice (control, n = 7; liraglutide, n = 9), and (C) in TLR4KO mice with DSS colitis (control, n = 5; liraglutide, n = 4). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by non-paired t-test (A–C). All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).CC BY · PubMed Central
Figure 6 In DSS colitis, liraglutide promotes bacterial translocation. (A) Correlation between the relative expression of ClpB in cecal contents and occludin in cecal tissue in mice with DSS colitis with or without acute liraglutide administration (total, n = 18; liraglutide, n = 11). (B) ClpB positive rate in the spleen under DSS colitis conditions in wild-type (WT) mice and TLR4KO mice with or without acute liraglutide administration (WT control, n = 7; WT liraglutide, n = 9; TLR4KO control, n = 5; TLR4KO liraglutide, n = 4). (C) Cecal occludin gene expressions according to ClpB positivity (bacterial translocation [BT]) under DSS colitis conditions in wild-type (WT) mice and TLR4KO mice (WT BT-positive, n = 6; WT BT-negative, n = 10; TLR4KO BT-positive, n = 8). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by linear regression analysis (A), two-way ANOVA with multiple comparison test (B), and one-way ANOVA with multiple comparison test (C). The coefficient of determination is denoted as R2. All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).
Figure 6 In DSS colitis, liraglutide promotes bacterial translocation. (A) Correlation between the relative expression of ClpB in cecal contents and occludin in cecal tissue in mice with DSS colitis with or without acute liraglutide administration (total, n = 18; liraglutide, n = 11). (B) ClpB positive rate in the spleen under DSS colitis conditions in wild-type (WT) mice and TLR4KO mice with or without acute liraglutide administration (WT control, n = 7; WT liraglutide, n = 9; TLR4KO control, n = 5; TLR4KO liraglutide, n = 4). (C) Cecal occludin gene expressions according to ClpB positivity (bacterial translocation [BT]) under DSS colitis conditions in wild-type (WT) mice and TLR4KO mice (WT BT-positive, n = 6; WT BT-negative, n = 10; TLR4KO BT-positive, n = 8). All values represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant by linear regression analysis (A), two-way ANOVA with multiple comparison test (B), and one-way ANOVA with multiple comparison test (C). The coefficient of determination is denoted as R2. All figures were drawn using GraphPad Prism 7 (www.graphpad.com) and Microsoft’s PowerPoint 2016 (www.microsoft.com).CC BY · PubMed Central
Figure 7 Schematic of this experiment. Acute administration of liraglutide causes these three phenomena: (1) sympathetic nervous system (SNS) activation and release of norepinephrine to the intestinal lumen, (2) increased levels of E. coli in cecal contents, and (3) promotion of bacterial translocation under stress conditions, such as colitis. This image was drawn using Microsoft’s PowerPoint 2016 (www.microsoft.com).
Figure 7 Schematic of this experiment. Acute administration of liraglutide causes these three phenomena: (1) sympathetic nervous system (SNS) activation and release of norepinephrine to the intestinal lumen, (2) increased levels of E. coli in cecal contents, and (3) promotion of bacterial translocation under stress conditions, such as colitis. This image was drawn using Microsoft’s PowerPoint 2016 (www.microsoft.com).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 62 · Cited by 59

Metadata

Authors
Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y.
Affiliations
Akita University (JP)
Corresponding author
Yamada, Yuichiro
Venue
Scientific Reports
Published
2021-04-28
Volume
11
Issue
1
Pages
9167-9167
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3159698927
Cited by
59
References
62
Citations by year
2026: 12 · 2025: 23 · 2024: 9 · 2023: 9 · 2022: 5 · 2021: 1
FWCI
1.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
Funders
  • Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (18H03171)
  • the Japan Agency for Medical Research and Development (JP18ek0210111)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, liraglutide, gut microbiota, Escherichia coli, norepinephrine, sympathetic nervous system, chemical sympathectomy, intermediolateral nucleus, c-fos, bacterial translocation, colitis, tight junction gene expression, metabolic disorders
MeSH terms
Glucagon-Like Peptide-1 Receptor, Gastrointestinal Microbiome, Liraglutide, Fecal Microbiota Transplantation, Glucagon-Like Peptide-1 Receptor Agonists, Adrenalectomy, Animals, Appetite, Cecum, Colitis, Escherichia coli, Heat-Shock Proteins, Mice, Inbred C57BL, Norepinephrine, Sympathetic Nervous System, Proto-Oncogene Proteins c-fos, Escherichia coli Proteins, Endopeptidase Clp, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. https://app.cochat.ai/papers/10.1038/s41598-021-88612-x
The paper
Kato, S., Sato, T., Fujita, H., Kawatani, M., & Yamada, Y. (2021). Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms. Scientific Reports. https://doi.org/10.1038/s41598-021-88612-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.